Just when you think you have enough things to worry about, you stumble upon one more. In its wisdom, Congress enacted a “Medicare Drug Price Negotiation Plan” as part of the Inflation Reduction Act. The program kicks in by imposing “maximum fair prices” for drugs as determined by the Centers for Medicare & Medicaid Services (CMS). In setting these prices, Congress included such factors as the R&D costs for each drug and whether they have been recovered and the current cost of producing and distributing the drug in question. But it was the third criteria which caught my eye—“Prior Federal financial support for novel therapeutic discovery and development with respect to the drug.”
Recent Posts
- Agency’s Acting Deputy Director Says It’s Back to Basics for the USPTO
- Quantum Computers and the Evolution of AI | IPWatchdog Unleashed
- Second C4IP Congressional Scorecard Finds Pro-Innovation Efforts Lacking Among Most DC Lawmakers
- Other Barks & Bites for Friday, May 30: Eighth Circuit Avoids Knowledge Standard Question Left by Unicolors; SCOTUS Denies Petition on Enablement Standard for Prior Art; USIJ Urges FTC to Look at PTAB Abuse
- Examining the Intellectual Property-Relevant Provisions in the ‘Big Beautiful Bill’